Clinical Trials Browser

Recruiting × Graft vs Host Disease × fludarabine × Clear all

Graft vs Host Disease, Hematologic Neoplasms

NCT04678401 2025-10-20

IS-free Treg HaploHCT

Phase 1 Recruiting

30 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Phase 2 Recruiting

35 enrolled

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05005299 2023-08-01

VICTORY

Phase 1 Recruiting

18 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03852407 2022-10-12

HLA

Phase 2 Recruiting

114 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, B-Cell, Hematologic Neoplasms

Clinical Trials

CY-MET-RIC

IS-free Treg HaploHCT

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

VICTORY

HLA